Tübingen. This should enable the effectiveness of the vaccine candidate CVnCoV to be determined in specific variants, said Curevac in a message on Monday. The effectiveness of the vaccine candidate is currently being investigated in the already advanced study in Europe and Latin America with around 35,000 participants. Curevac confirmed that it intends to apply for marketing authorization in the second quarter of 2021. The company expects approval by the end of June.
By expanding the study analysis, it should also be possible to record the relevant efficacy data of the important group of around 270 participants over 60 years of age who have received a vaccination with twelve micrograms. “Our goal is to protect the population and especially the older age groups at risk from the virus and its mutations with our vaccine candidate,” the message said. The advanced analysis could make better use of data from older adults.
In autumn 2020, Curevac started building a European network for vaccine production with several service partners. So far, Curevac has signed agreements with Bayer, Fareva, Wacker, Rentschler and others. Like the vaccine from Biontech and its US partner Pfizer, the Curevac vaccine is based on the messenger molecule mRNA, which stimulates the formation of a virus protein in the body. This triggers an immune response that is supposed to protect people from the virus. The European Medicines Agency (EMA) started the rapid testing process for the Curevac vaccine in February.